Clinical Trials - April 12, 2019
BerGenBio extends Phase II trial
The first patient has been dosed in an additional cohort (“Cohort B”) of an ongoing phase II open-label study of BerGenBio’s selective AXL inhibitor bemcentinib in combination with Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) in previously treated patients with advanced adenocarcinoma of the lung (NSCLC). The additional cohort of the BGBC008 trial, being run in collaboration with Merck, […]
Drug Development Pharma - January 29, 2018
BerGenBio shows encouranging results
BerGenBio announces the presentation of data from its broad phase II clinical development programme with its selective AXL inhibitor bemcentinib (BGB324) in two posters at the ASCO-SITC Clinical Immuno-Oncology Symposium (January 25-27, San Francisco, CA, USA). One poster outlined favourable interim safety data from three phase II clinical trials with bemcentinib in combination with KEYTRUDA (pembrolizumab), […]
Clinical Trials - January 9, 2018
BerGenBio meets efficacy endpoint
The first efficacy endpoint has been met in its phase II clinical trial evaluating BGB324 (bemcentinib), a selective AXL inhibitor, in combination with erlotinib in patients with advanced non-small cell lung cancer (NSCLC) who have progressed on an approved EGFR inhibitor. The trial The trial (known as BGBC004) is designed to test the hypothesis that […]
Biotech Business - June 27, 2017
BerGenBio awarded NOK 24m from Innovasjon Norge
BerGenBio announces the award of a NOK 24 million (USD 2.85m) grant from Innovasjon Norge to support the clinical development of BGB324 in combination with Merck & Co.’s KEYTRUDA (pembrolizumab) in patients with advanced lung cancer. BerGenBio will sponsor a Phase II study multi-centre study of BGB324 in combination with KEYTRUDA in patients with previously […]
Clinical Trials - May 22, 2017
BerGenBio starts Phase I/II trial
BerGenBio announces that the first patients have been dosed and continue on therapy in a Phase I/II randomised trial evaluating the addition of BerGenBio’s selective, potent and orally bio-available AXL inhibitor BGB324 to standard of care treatments in patients with advanced, non-resectable or metastatic melanoma. The trial, which is sponsored by Haukeland University Hospital (Bergen, […]
Listing - March 29, 2017
BerGenBio announces the terms of its IPO
Further to the announcement on 8 March 2017 regarding the intention to list the shares of BerGenBio ASA on Oslo Børs and carry out an Initial Public Offering, BerGenBio announces the terms of the IPO. Subject to approval of the listing application and the successful completion of the IPO, the shares of BerGenBio are expected […]
